These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 17012539)

  • 41. Pharmacokinetics, metabolism, and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in rats and rhesus monkeys.
    Tan EY; Hartmann G; Chen Q; Pereira A; Bradley S; Doss G; Zhang AS; Ho JZ; Braun MP; Dean DC; Tang W; Kumar S
    Drug Metab Dispos; 2010 Mar; 38(3):459-73. PubMed ID: 20016052
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Absorption, distribution and excretion of [carbonyl-14C]mosapride citrate after a single oral administration in rats, dogs and monkeys.
    Matsumoto S; Tagawa M; Amejima H; Nakao M; Kagemoto A; Fujii T; Miyazaki H; Sekine Y
    Arzneimittelforschung; 1993 Oct; 43(10):1084-94. PubMed ID: 8267675
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Discovery of thiazolidine-2,4-dione/biphenylcarbonitrile hybrid as dual PPAR α/γ modulator with antidiabetic effect: in vitro, in silico and in vivo approaches.
    Hidalgo-Figueroa S; Ramírez-Espinosa JJ; Estrada-Soto S; Almanza-Pérez JC; Román-Ramos R; Alarcón-Aguilar FJ; Hernández-Rosado JV; Moreno-Díaz H; Díaz-Coutiño D; Navarrete-Vázquez G
    Chem Biol Drug Des; 2013 Apr; 81(4):474-83. PubMed ID: 23289972
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Disposition and metabolism of olanzapine in mice, dogs, and rhesus monkeys.
    Mattiuz E; Franklin R; Gillespie T; Murphy A; Bernstein J; Chiu A; Hotten T; Kassahun K
    Drug Metab Dispos; 1997 May; 25(5):573-83. PubMed ID: 9152596
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics and disposition of DY-9760e, a novel calmodulin antagonist, in rats and monkeys.
    Tachibana S; Fujimaki Y; Tachibana M; Tanaka M; Kurata T; Okazaki O; Sudo K
    Arzneimittelforschung; 2005; 55(3):135-44. PubMed ID: 15819385
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Disposition and metabolism of amosulalol hydrochloride, a new combined alpha- and beta-adrenoceptor blocking agent, in rats, dogs and monkeys.
    Sasaki H; Kamimura H; Kaniwa H; Kawamura S; Takaichi M; Yokoshima T
    Xenobiotica; 1984 Aug; 14(8):621-31. PubMed ID: 6149657
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Non-clinical safety evaluation and risk assessment to human of aleglitazar, a dual PPAR α/γ agonist, and its major human metabolite.
    Bopst M; Atzpodien EA
    Regul Toxicol Pharmacol; 2017 Jun; 86():107-116. PubMed ID: 28274810
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Absorption, distribution, metabolism, and excretion of tirzepatide in humans, rats, and monkeys.
    Martin JA; Czeskis B; Urva S; Cassidy KC
    Eur J Pharm Sci; 2024 Nov; 202():106895. PubMed ID: 39243911
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetics and disposition of CS-0777, a sphingosine 1-phosphate receptor modulator, in rats and monkeys.
    Inaba S; Ikeda T; Goto M; Tanaka H; Takahashi M; Iwabuchi H; Izumi T
    Xenobiotica; 2015; 45(12):1063-80. PubMed ID: 26084376
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Peroxisome proliferator-activated receptor (PPAR)-alpha agonism prevents the onset of type 2 diabetes in Zucker diabetic fatty rats: A comparison with PPAR gamma agonism.
    Bergeron R; Yao J; Woods JW; Zycband EI; Liu C; Li Z; Adams A; Berger JP; Zhang BB; Moller DE; Doebber TW
    Endocrinology; 2006 Sep; 147(9):4252-62. PubMed ID: 16728496
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Metabolism and disposition of a potent and selective JNK inhibitor [14C]tanzisertib following oral administration to rats, dogs and humans.
    Atsriku C; Hoffmann M; Ye Y; Kumar G; Surapaneni S
    Xenobiotica; 2015 May; 45(5):428-41. PubMed ID: 25482583
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Disposition of a low dose of 14C-bisphenol A in male rats and its main biliary excretion as BPA glucuronide.
    Kurebayashi H; Betsui H; Ohno Y
    Toxicol Sci; 2003 May; 73(1):17-25. PubMed ID: 12700409
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Metabolism and disposition of [14C]brivanib alaninate after oral administration to rats, monkeys, and humans.
    Gong J; Gan J; Caceres-Cortes J; Christopher LJ; Arora V; Masson E; Williams D; Pursley J; Allentoff A; Lago M; Tran SB; Iyer RA
    Drug Metab Dispos; 2011 May; 39(5):891-903. PubMed ID: 21289073
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacokinetics and metabolism of the prodrug DB289 (2,5-bis[4-(N-methoxyamidino)phenyl]furan monomaleate) in rat and monkey and its conversion to the antiprotozoal/antifungal drug DB75 (2,5-bis(4-guanylphenyl)furan dihydrochloride).
    Midgley I; Fitzpatrick K; Taylor LM; Houchen TL; Henderson SJ; Wright SJ; Cybulski ZR; John BA; McBurney A; Boykin DW; Trendler KL
    Drug Metab Dispos; 2007 Jun; 35(6):955-67. PubMed ID: 17360833
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.
    Bajaj M; Suraamornkul S; Hardies LJ; Glass L; Musi N; DeFronzo RA
    Diabetologia; 2007 Aug; 50(8):1723-31. PubMed ID: 17520238
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetics of 4-acetylaminophenylacetic acid. 1st communication: absorption, distribution, metabolism and excretion in mice, rats, dogs and monkeys after single administration of 14C-labeled compound.
    Sugihara K; Morino A; Nomura A; Iida S; Sugiyama M
    Arzneimittelforschung; 1990 Jul; 40(7):800-5. PubMed ID: 2222556
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Assessment of dose proportionality of muraglitazar after repeated oral dosing in rats via a sparse sampling methodology.
    Yao M; Swaminathan A; Srinivas N
    Biopharm Drug Dispos; 2007 Jan; 28(1):35-42. PubMed ID: 17117455
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Orally active inhibitors of human leukocyte elastase. II. Disposition of L-694,458 in rats and rhesus monkeys.
    Vincent SH; Painter SK; Luffer-Atlas D; Karanam BV; McGowan E; Cioffe C; Doss G; Chiu SH
    Drug Metab Dispos; 1997 Aug; 25(8):932-9. PubMed ID: 9280401
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs.
    Beconi MG; Reed JR; Teffera Y; Xia YQ; Kochansky CJ; Liu DQ; Xu S; Elmore CS; Ciccotto S; Hora DF; Stearns RA; Vincent SH
    Drug Metab Dispos; 2007 Apr; 35(4):525-32. PubMed ID: 17220241
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Metabolism and disposition of moxonidine in Fischer 344 rats.
    He MM; Abraham TL; Lindsay TJ; Chay SH; Czeskis BA; Shipley LA
    Drug Metab Dispos; 2000 Apr; 28(4):446-59. PubMed ID: 10725314
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.